A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Inclusion Criteria:

• Participant must have at least 1 measurable lesion, according to Response EvaluationCriteria in Solid Tumors (RECIST) version 1.1, that has not been previouslyirradiated

• Participant must have histologically or cytologically confirmed, locally advanced ormetastatic, non-squamous non-small cell lung cancer (NSCLC), characterized at orafter the time of locally advanced or metastatic disease diagnosis by eitherepidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation

• A participant with a history of brain metastases must have had all lesions treatedas clinically indicated (that is, no current indication for further definitive localtherapy). Any definitive local therapy to brain metastases must have been completedat least 14 days prior to randomization and the participant can be receiving nogreater than10 milligrams (mg) prednisone or equivalent daily for the treatment ofintracranial disease

• Participant must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

• Any toxicities from prior systemic anticancer therapy must have resolved to NationalCancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade <= 2peripheral neuropathy, or Grade <= 2 hypothyroidism stable on hormone replacement)

• A participant of childbearing potential must have a negative serum pregnancy test atscreening and within 72 hours of the first dose of study treatment and must agree tofurther serum or urine pregnancy tests during the study

• Participant must have progressed on or after osimertinib monotherapy as the mostrecent line of treatment. Osimertinib must have been administered as either thefirst-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosinekinase inhibitor (TKI) as a monotherapy. Participants who received eitherneoadjuvant and/or adjuvant treatment of any type are eligible if progression tolocally advanced or metastatic disease occurred at least 12 months after the lastdose of such therapy and then the participant progressed on or after osimertinib inthe locally advanced or metastatic setting. Treatment with osimertinib must bediscontinued at least 8 days (4 half-lives) prior to randomization (that is lastdose no later than Day -8)

Exclusion Criteria:

• Participant received radiotherapy for palliative treatment of NSCLC less than 14days prior to randomization

• Participant with symptomatic or progressive brain metastases

• Participant has history of or current evidence of leptomeningeal disease, orparticipant has spinal cord compression not definitively treated with surgery orradiation

• Participant has known small cell transformation

• Participant has a medical history of interstitial lung disease (ILD), includingdrug-induced ILD or radiation pneumonitis

• Participant has a history of clinically significant cardiovascular diseaseincluding, but not limited to diagnosis of deep vein thrombosis or pulmonaryembolism within 4 weeks prior to randomization; myocardial infarction; unstableangina; stroke; transient ischemic attack; coronary/peripheral artery bypass graft;or acute coronary syndrome. Participant has a significant genetic predisposition tovenous thromboembolic events. Participant has a prior history of venousthromboembolic events and is not on appropriate therapeutic anticoagulation as perNational Comprehensive Cancer Network or local guidelines